Company Filing History:
1 out of 2,493 
1 out of 1,162 
1 out of 1,871 
Years Active: 2011
Title: The Innovative Contributions of Nick Giannoukakls
Introduction
Nick Giannoukakls is a notable inventor based in Coraopolis, Pennsylvania. He has made significant strides in the field of biotechnology, particularly in the treatment of autoimmune diseases. His work focuses on the delivery of antisense oligonucleotides, which has the potential to revolutionize therapies for conditions like type 1 diabetes.
Latest Patents
Giannoukakls holds a patent for the "Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes." This innovative approach utilizes microspheres to deliver AS-oligonucleotides, aiming to induce dendritic cell tolerance specifically in the non-obese-diabetic (NOD) mouse model. The process involves targeting primary transcripts CD40, CD80, and CD86, which are crucial in preventing autoimmune diabetes.
Career Highlights
Throughout his career, Giannoukakls has worked with prominent companies such as Baxter International Inc. and Baxter Healthcare. His experience in these organizations has contributed to his expertise in developing advanced therapeutic solutions.
Collaborations
Some of his notable coworkers include Larry Richard Brown and Vered Bisker-Leib. Their collaborative efforts have further enhanced the research and development of innovative treatments in the field.
Conclusion
Nick Giannoukakls is a pioneering inventor whose work in antisense oligonucleotide delivery holds promise for treating autoimmune diseases. His contributions to biotechnology are noteworthy and continue to impact the field positively.